- Recce Pharmaceuticals (RCE) reports no adverse symptoms so far from its clinical trial in Perth, WA
- Patients have been dosed with the spray-on RECCE 327 in a topical Phase I/II clinical trial at the Fiona Stanley Hospital Burns Unit
- The trial will take place over 14 days, with the treatment well-stocked in the hospital pharmacy for further patient utilisation
- The company says interim data readouts are expected this quarter with full data expected to be presented at the end of Q4 2021
- Recce Pharmaceuticals last traded at 91 cents on July 9
Recce Pharmaceuticals (RCE) has begun dosing multiple patients as part of its clinical trial in Perth, WA.
Participants have been dosed with RECCE 327 (R327) in a topical Phase I/II clinical trial at the Fiona Stanley Hospital Burns Unit.
The study aims to assess the clinical effectiveness and safety of R327 as a spray-on antibiotic to treat infected burn wounds in adults.
The trial is being sponsored by the WA Health Department and will see patients undergoing two dosing schedules, with ten participants receiving daily R327 treatments, and the other twenty patients receiving the spray-on treatment three times a week over a 14-day study period.
Clinical Investigator Dr Edward Raby said there is a major unmet medical need among patients with severe burn wound infections with this important study a key part in our work to find a solution.
Burn wound infections continue to cause significant health problems for patients following a range of burn injuries. Despite this, current therapeutic options are sub-optimal and are often associated with delayed healing.
“The spray-on administration makes application easy, with the potential patient benefit having real world impact beyond,” said Dr Edward Raby.
So far, no adverse symptoms have been reported, with R327 well stocked in hospital pharmacy for further patient utilisation.
The company says interim data readouts are expected this quarter with the full data expected to be presented at the end of Q4 2021.
Recce Pharmaceuticals last traded at 91 cents on July 9.